Research Progress in the Efficacy and Safety of ALK Inhibitors
in the Treatment of NSCLC Brain Metastasis.
10.3779/j.issn.1009-3419.2023.101.10
- Author:
Yuchen CHEN
1
;
Han HAN
1
;
Jinpan WEI
1
;
Qianyu DU
1
;
Xiyong WANG
1
Author Information
1. Department of Oncology, Suzhou Hospital of Anhui Medical University (Suzhou Municipal Hospital of Anhui Province),
Suzhou 234000, China.
- Publication Type:Journal Article
- Keywords:
ALK inhibitors;
Brain metastasis;
Efficacy;
Lung neoplasms;
Safety
- MeSH:
Humans;
Carcinoma, Non-Small-Cell Lung/drug therapy*;
Lung Neoplasms/drug therapy*;
Brain Neoplasms/drug therapy*;
Protein Kinase Inhibitors/adverse effects*;
Crizotinib
- From:
Chinese Journal of Lung Cancer
2023;26(5):400-406
- CountryChina
- Language:Chinese
-
Abstract:
Lung cancer is one of the most lethal malignancies in the world, with non-small cell lung cancer (NSCLC) accounting for approximately 80%-85% of all pathological types. Approximately 30%-55% of NSCLC patients develop brain metastases. It has been reported that 5%-6% of patients with brain metastases harbor anaplastic lymphoma kinase (ALK) fusion. ALK-positive NSCLC patients have shown significant therapeutic benefits after treatment with ALK inhibitors. Over the past decade, ALK inhibitors have rapidly evolved and now exist in three generations: first-generation drugs such as Crizotinib; second-generation drugs including Alectinib, Brigatinib, Ceritinib, and Ensartinib; and third-generation drugs like Lorlatinib. These drugs have exhibited varying efficacy in treating brain metastases in ALK-positive NSCLC patients. However, the numerous options available for ALK inhibition present a challenge for clinical decision-making. Therefore, this review aims to provide clinical guidance by summarizing the efficacy and safety of ALK inhibitors in treating NSCLC brain metastases.
.
